Business
Immune Therapeutics, Inc. Provides Drug Development Program Status Update on Methionine-Enkelphine ("MENK") in China
Immune Therapeutics, Inc. Provides Drug Development Program Status Update on Methionine-Enkelphine ("MENK") in China.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nImmune Therapeutics, Inc. Provides Drug Development Program Status Update on Methionine-Enkelphine (\"MENK\") in China\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nImmune Therapeutics, Inc. Provides Drug Development Program Status Update on Methionine-Enkelphine (\"MENK\") in China\nPR Newswire\nORLANDO Fla., April 11, 2016\n\n\n\nORLANDO Fla., April 11, 2016 /PRNewswire/ -- Immune Therapeutics, Inc. (OTCQB: IMUN); a clinical-stage international biotechnology company providing immunotherapy solutions for the treatment of diseases, autoimmune diseases, and cancer, announced today it is providing shareholders with a status update of Immune Therapeutics, Inc.'s (IMUN) drug development program in China with long-term partner Hubei Qianjiang Pharmaceutical Co. Ltd (Qianjiang).\n\nThe Economist Intelligence Unit (EIU) projects $166 billion in drug sales in China by 2017, providing a recognized market to  further growth. China, potentially one of the largest pharmaceutical markets in the world, is not yet mature. The combined forces of economic and demographic development, government stimulus, enhanced health awareness among the public, market consolidation, and improved R&D capabilities will help the country to mature into a sophisticated market within the next decade. \n\nNoreen Griffin, CEO of Immune Therapeutics, Inc. said, \"In an effort to keep our shareholders informed about our drug development program for MENK, our unique immunotherapy for the treatment of cancer, we are providing this update.\"\n\nChinese Peptide Company (CPC) (http://www.chinesepeptide.com) has completed the formulation and the required Chemistry, Manufacturing, and Controls (\"CMC\") for MENK.  All work was completed in China in accordance with international cGMP standards, which are acceptable to the U.S. Food and Drug Administration. CPC is among only a handful of companies in the world that can claim both ISO Certification and cGMP licensing. In February 2012, CPC became the first peptide company to successfully pass US FDA inspection outside of US and Europe regions...